Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of MEDI1341 in Subjects With Parkinson's Disease

NCT04449484 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04449484
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04449484 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of MEDI1341 in Subjects With Parkinson's Disease
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
August 4, 2020
Completion date
January 5, 2022
Enrollment
25 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease